Abstract Details

Title Prospective Trial of Rituximab in Patients with Intravenous Immune Globulin (IVIG) Dependent Chronic Relapsing Immune Polyneuropathies

Topic Peripheral Nerve

Presentation(s) (-)

Poster/Presentation
Number 107

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Kenneth C. Gorson, MD (Kenneth Gorson, MD)	Dr. Gorson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Annexon. Dr. Gorson has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Gorson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ArgenX. Dr. Gorson has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer.
Adrian Williams	No disclosure on file
	No disclosure on file
Robert Wilson	No disclosure on file
	No disclosure on file
Violaine K. Harris, PhD (Tisch Multiple Sclerosis Research Center of NY)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Allan H. Ropper, MD, FAAN (New England Journal of Medicine)	No disclosure on file
	No disclosure on file
	No disclosure on file
Neha Dangayach, MD, FAAN (Icahn School of Medicine At Mount Sinai and Mount Sinai Hospital)	Dr. Dangayach has nothing to disclose.
	No disclosure on file
Errol L. Gordon, MD (Neurology & Stroke)	No disclosure on file
Shuhab M. Zaher	No disclosure on file
Anil Ramineni, MD	Dr. Ramineni has nothing to disclose.
	No disclosure on file
Javaad Ahmad, MD (Good Samaritan Hospital)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Stephan A. Mayer, MD (Henry Ford Hospital)	Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Phagenesis. Dr. Mayer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ISchemaView. Dr. Mayer has stock in Neuroptics. Dr. Mayer has received publishing royalties from a publication relating to health care.